2026 CG Musculoskeletal Conference
Logotype for Shoulder Innovations Inc

Shoulder Innovations (SI) 2026 CG Musculoskeletal Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Shoulder Innovations Inc

2026 CG Musculoskeletal Conference summary

4 Mar, 2026

Market overview and growth

  • Shoulder arthroplasty is a sub-$3 billion market growing at over 10% annually, with the reverse shoulder style now representing over 70% of procedures worldwide.

  • Trailing twelve-month revenue reached $42 million at the end of Q3 2025, reflecting a 55% CAGR over the prior eight quarters and a 76% gross margin.

  • Outpatient procedures, especially in Ambulatory Surgery Centers, are rapidly increasing, now accounting for over 30% of procedures after a positive CMS payment decision in January 2024.

  • Growth is driven by high-volume surgeons, with 1,800 targeted specialists and 95% of revenue from core and contender customers growing over 50% year-over-year.

  • Expansion into international markets is planned for the coming quarters, with all current revenue from the U.S.

Technology and innovation

  • Proprietary InSet glenoid implant addresses glenoid loosening, reducing rocking horse motion by 87% and achieving up to 100% survivorship at nine years.

  • AI-enabled ProVoyance 3D preoperative planning platform is fully adopted by surgeons and central to product deployment and customer engagement.

  • Two Tray platform system simplifies surgical workflow, reduces costs, and is tailored for Ambulatory Surgery Centers.

  • Recent product introductions include the I-135 platform for fracture indications and N22 Glenospheres for metal hypersensitivity, both in limited user release.

  • Partnership with Interventional Systems enables a portable, robotics-as-a-service model, aiming for time-neutral, capital-light deployment in operating rooms.

Commercial strategy and future outlook

  • Unique commercial model combines a 1099 indirect distribution network with a focused W-2 commercial and customer experience team.

  • Focused on high-volume surgeons, with a man-demand approach to relationship building and product adoption.

  • New products are positioned at higher price points, supporting price stabilization in a typically deflationary orthopedic market.

  • Robotics solution is not yet in market but has generated significant interest and positive perception among surgeons.

  • Future growth drivers include international expansion and potential entry into additional soft tissue indications.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more